Abstract
Elucidating the genetic contributions to Parkinson’s disease (PD) etiology across diverse ancestries is a critical priority for the development of targeted therapies in a global context. We conducted the largest sequencing characterization of potentially disease-causing, protein-altering and splicing mutations in 710 cases and 11,827 controls from genetically predicted African or African admixed ancestries. We explored copy number variants (CNVs) and runs of homozygosity (ROHs) in prioritized early onset and familial cases. Our study identified rare GBA1 coding variants to be the most frequent mutations among PD patients, with a frequency of 4% in our case cohort. Out of the 18 GBA1 variants identified, ten were previously classified as pathogenic or likely pathogenic, four were novel, and four were reported as of uncertain clinical significance. The most common known disease-associated GBA1 variants in the Ashkenazi Jewish and European populations, p.Asn409Ser, p.Leu483Pro, p.Thr408Met, and p.Glu365Lys, were not identified among the screened PD cases of African and African admixed ancestry. Similarly, the European and Asian LRRK2 disease-causing mutational spectrum, including LRRK2 p.Gly2019Ser and p.Gly2385Arg genetic risk factors, did not appear to play a major role in PD etiology among West African-ancestry populations. However, we found three heterozygous novel missense LRRK2 variants of uncertain significance overrepresented in cases, two of which — p.Glu268Ala and p.Arg1538Cys — had a higher prevalence in the African ancestry population reference datasets. Structural variant analyses revealed the presence of PRKN CNVs with a frequency of 0.7% in African and African admixed cases, with 66% of CNVs detected being compound heterozygous or homozygous in early-onset cases, providing further insights into the genetic underpinnings in early-onset juvenile PD in these populations. Novel genetic variation overrepresented in cases versus controls among screened genes warrants further replication and functional prioritization to unravel their pathogenic potential. Here, we created the most comprehensive genetic catalog of both known and novel coding and splicing variants potentially linked to PD etiology in an underserved population. Our study has the potential to guide the development of targeted therapies in the emerging era of precision medicine. By expanding genetics research to involve underrepresented populations, we hope that future PD treatments are not only effective but also inclusive, addressing the needs of diverse ancestral groups.
Competing Interest Statement
KL, DV, HLL, HI, MJK and MAN declare that they are consultants employed by DataTecnica LLC, whose participation in this is part of a consulting agreement between the US National Institutes of Health and said company. MAN also owns stock from Neuron23 Inc and Character Biosciences.
Clinical Protocols
https://github.com/GP2code/PD-GeneticCharacterization-inAFRandAAC/
Funding Statement
This work utilized the computational resources of the NIH HPC Biowulf cluster (https://hpc.nih.gov). This research was supported in part by the Intramural Research Program of the NIH, National Institute on Aging (NIA), National Institutes of Health, Department of Health and Human Services; project number ZO1 AG000535 and ZIA AG000949, as well as the National Institute of Neurological Disorders and Stroke (NINDS, program # ZIANS003154) and the National Human Genome Research Institute (NHGRI). This work utilized the computational resources of the NIH STRIDES Initiative (https://cloud.nih.gov) through the Other Transaction agreement - Azure: OT2OD032100, Google Cloud Platform: OT2OD027060, Amazon Web Services: OT2OD027852. Data used in the preparation of this article were obtained from the Global Parkinson′s Genetics Program (GP2). GP2 is funded by the Aligning Science Across Parkinson′s (ASAP) initiative and implemented by The Michael J. Fox Foundation for Parkinson′s Research (https://gp2.org). For a complete list of GP2 members see https://gp2.org. Additional funding was provided by The Michael J. Fox Foundation for Parkinson′s Research through grant MJFF-009421/17483.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All GP2 data for these analyses is available through collaboration with Accelerating Medicines Partnership in Parkinson′s disease and is available through application on the AMP—PD website. Other publicly available data consortiums include All of Us Research Program and UK Biobank, in which data can be accessed after applying. We have received an exception to the Data and Statistics Dissemination Policy from the All of Us Resource Access Board.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Some typological errors of the author names and their affiliations were updated. Supplementary table 4 was updated, to remove the frequency of the Nigerian cohort from the total frequency estimation. The text related to Supplementary Table 4 was revised accordingly.
Data availability
All GP2 data for these analyses is available through collaboration with Accelerating Medicines Partnership in Parkinson’s disease and is available through application on the AMP-PD website (https://amp-pd.org/register-for-amp-pd). Other publicly available data consortiums include All of Us Research Program (https://www.researchallofus.org/register/) and UK Biobank (https://www.ukbiobank.ac.uk/enable-your-research/register), in which data can be accessed after applying. We have received an exception to the Data and Statistics Dissemination Policy from the All of Us Resource Access Board.
